Return to Course LibraryCE InformationPrint Course MaterialsBibliography

Original Release Date

Review Date
May 10, 2016

Expiration Date
June 1, 2017





Stephen W. Phillips, MD, FACR
Medical Director
Methodist Sugar Land Hospital Breast Center
Assistant Professor of Radiology
Weill Cornell Medical College





Equipment Requirements:
PC: Win7/Win8, Pentium processor or faster, at least 2GB RAM, Internet Explorer version 10/11, Mozilla FireFox version 33.0.

MAC: OS version 10.8/10.9, Intel processor, at least 2GB RAM, Safari version 6.2, FireFox 33.0



5600-101A Molecular Breast Imaging: Clinical Indications, Benefits, and Challenges

A certified one-hour recorded presentation on molecular breast imaging for radiologists, interventional radiologists, radiologic technologists, physicians, and other healthcare professionals who diagnose and treat breast cancer.


Format: Online Course
MD or nonMD      Credit:  1.0 AMA PRA Category 1
MD or nonMD      Fee:          $25.00     $5

RT                         Credit:    1.0 ARRT Catogory A+
RT                         Fee:          
$10          $5


Click ENROLL NOW to register for this program

Course Overview
Breast cancer remains the second cause of cancer death in the United States, and the probability of dying from breast cancer is 3% (1). Approximately 39,620 women and 410 men will die from breast cancer in 2013 (2). It has been shown that about 40% of women have dense breast tissue (3, 4), and several studies have shown that mammographic breast density is associated with increased risk of breast cancer, making detection of cancer by traditional mammography difficult (3, 4, 5).

With a growing number of imaging modalities, radiologists are charged with counseling patients and selecting the best available breast imaging modality for screening and diagnosis of breast cancer.

As part of the breast imaging armamentarium, molecular breast imaging has shown to be sensitive to the identification of subcentimeter lesions in the setting of dense breast tissue or for abnormal exams (6, 7, 8).

In this educational activity, faculty will introduce the learner to the function of the radiotracer and subsequent tissue response at the molecular level, how MBI can impact patient care, and benefits and challenges of MBI.

  1. National Cancer Institute website. Breast Cancer. Available at:  Accessed August 13, 2013.
  2. American Cancer Society website. Breast Cancer Facts & Figures 2011-2012. Available at: Research/CancerFactsFigures/BreastCancerFactsFigures/breast-cancer-facts-and-figures-2011-2012  Accessed October 12, 2012.
  3. Weigert J, Steenbergen S. The connecticut experiment: the role of ultrasound in the screening of women with dense breasts. Breast J. 2012;18(6):517-522.
  4. Garcia-Lallana A, Mendiguren RS, Iba┼łez IA, Elizalde A, Martinez-Regueira F, Pina LJ. The role of ultrasound after normal mammography in density ACR patterns 2, 3, and 4 in the detection of breast cancer. Paper presented at: Radiological Society of North America; November 28, 2011; Chicago, IL.
  5. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1159-1169.
  6. O'Connor M, Rhodes D, Hruska C. Molecular breast imaging. Expert Rev Anticancer Ther. 2009;9(8):1073-1080.
  7. Sun Y, Wei W, Yang HW, Liu JL. Clinical usefulness of breast-specific gamma imaging as an adjunct modality to mammography for diagnosis of breast cancer: a systemic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2013; 40(3):450-463.
  8. Brem RF, Rechtman LR. Nuclear medicine imaging of the breast: a novel, physiologic approach to breast cancer detection and diagnosis. Radiol Clin North Am. 2010;48(5):1055-1074.

Educational Objectives
At the conclusion of this activity, participants should be better able to:

  • Assess the role of molecular breast imaging as a complementary tool to screening mammography
  • Describe patient indications for the use of molecular breast imaging
  • Evaluate the benefits and challenges of molecular breast imaging in screening for and diagnosing of breast cancer
  • Counsel patients with dense breast tissue about alternative screening options

Accreditation & Credit
ACCME Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and International Center for Postgraduate Medical Education.  The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

SA-CME: This activity meets the criteria for self-assessment toward the purpose of fulfilling requirements in the American Board of Radiology (ABR) Maintenance of Certification Program.

The European Accreditation Council for CME (EACCME®)
The UEMS-EACCME® has mutual recognition agreements with the American Medical Association (AMA) for live events and e-learning materials. For more information go to

Radiologic Technologists
This program has been approved by the American Society of Radiologic Technologists (ASRT) for 1.0 hours of ARRT Category A+ continuing education credit.

ICPME accepts American Express, MasterCard, and Visa.

Please note: tuition payments are non-refundable.

Tuition for this course includes:

  • Downloadable course content
  • Unlimited access to the course
  • Certificate of Credit

How to Enroll and Participate
There is a fee to register for this activity.There are no prerequisites for this program. Estimated time to complete this activity is one hour.

  • Click ENROLL NOW and follow the registration and payment instructions
  • Click the blue link to view the course.

How to Receive Credit

  • Log-in to your account at
  • View the entire one-hour session.
  • At the conclusion of the lecture, close the WebEx Player window.
  • From the COURSE HOME page, click the buttons for POSTTEST and for EVALUATION.
  • A passing grade of at least 75% is required to receive credit.  You may take the test up to three times.
  • Upon receipt of a passing grade, you will be able to print a certificate of credit from your account on Your online account with ICPME serves as a permanent record of credit certificates earned through

Faculty Biography

Stephen W. Phillips, MD, FACR
Dr. Phillips received his medical degree from University of Missouri – Columbia. He completed his residency in diagnostic radiology at University of Kentucky Medical Center and fellowships in CT and ultrasound at Dunedin Hospital, University of Otago, Dunedin, New Zealand and breast imaging and intervention at Lynn Sage Comprehensive Breast Center, Northwestern University Hospital, Chicago.

Formerly Assistant Professor of Radiology at Mayo Clinic, Dr. Phillips is currently the Medical Director at Methodist Sugar Land Hospital Breast Center, Sugar Land, Texas, and Assistant Professor of Radiology at Weill Cornell Medical College, New York.  He is also Co-Director of the Breast Imaging Fellowship program and Course Director for the Weekly Multidisciplinary Breast Tumor Board at the Methodist Hospital / Methodist Sugar Land Hospital, respectively.

Dr. Phillips has co-authored several peer-reviewed articles. His areas of clinical interest are breast imaging, molecular breast imaging, interventional devices, and breast cancer research.


Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The following faculty reported this financial relationship or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Stephen W. Phillips, MD, FACR has received consulting fees from Gamma Medica, Inc.

The following planners and managers reported NO financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Sharon Cancino
Laura Excell, ND, NP, MS, MA, LPC, NCC
Trace Hutchison, PharmD
Samantha Mattiucci, PharmD, CCMEP
Linda McLean, MS
Victoria Phoenix,BS
Jan Schultz, RN, MSN, CCMEP

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

For questions regarding this program, please contact ICPME:
Phone: 607-257-5860 X10



This activity was supported by independent educational grants from Gamma Medica, Inc. and GE Healthcare

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

©2013 ICPME. All rights reserved.